SciELO - Scientific Electronic Library Online

 
vol.9 issue3Pap test coverage and related factors in Colombia, 2005Developing an interlocution model for the health system based on studying the Colombian Guajira author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de Salud Pública

Print version ISSN 0124-0064

Abstract

CHICAIZA-BECERRA, Liliana A. et al. Economic impact of neumococcal vaccine on oncological patients. Rev. salud pública [online]. 2007, vol.9, n.3, pp.342-352. ISSN 0124-0064.

Objective An economic evaluation of an anti-S pneumoniae vaccine for oncological patients in Colombia. Methods As there is no evidence of vaccine effectiveness for this kind of patient, the cost of a vaccination programme for oncological patients was calculated during its first six years and the opportunity cost was estimated for early cancer detection alternatives. Results An anti-S. pneumoniae vaccination programme for oncological patients would cost around $31 000 000 000 (Colombian pesos in 2006, i.e. nearly US$12 400 000) during its first years. Alternative programs could be developed with this amount, such as 170 000 colonoscopies or early HPV detection, 500 000 mammographies, or more than 3 800 000 cytologies. Conclusions Given the scarcity of resources, it would be better (from an economic point of view) to devote this amount to programmes whose effectiveness has been proven, such as early cancer detection or vaccinating healthy children.

Keywords : Pneumococcal infection; economics; costs and cost analysis; vaccination; neoplasm.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License